GLASS, DAVID J.,YANCOPOULOS, GEORGE D.,DALY, THOMAS J.,PAPADOPOULOS, NICHOLAS J.
申请号：
CA2594023
公开号：
CA2594023C
申请日:
2006.01.06
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
A fusion protein comprising at least one IGF1 variant component and a fusioncomponent (F), and, optionally, a signal sequence, exhibiting improvedstability relative to the native IGF1 or IGF2 polypeptide. The fusioncomponent (F) may be a multimerizing component, a targeting ligand, or anotheractive or therapeutic compound. IGF1 variants were shown to have improvedability to induce skeletal muscle hypertrophy relative to native IGF1.
